| Ayman El-Guindy |
Ayman El-Guindy is Chief Scientific Officer of Viracta Therapeutics, Inc.
He received a doctorate and a graduate degree from Yale University and a graduate degree from Ain Shams University. |
| Douglas Faller |
Founder of HemaQuest Pharmaceuticals, Inc., Viracta Subsidiary, Inc. and Sapientia Pharmaceuticals, Inc., Douglas Faller is an entrepreneur who currently occupies the position of Chairman-Scientific Advisory Board at Viracta Therapeutics, Inc. and Scientific Founder at Sapientia Pharmaceuticals, Inc. He is also Professor at Boston University.
In the past Dr. Faller held the position of Faculty Member at Dana-Farber Cancer Institute, Inc. and Faculty Member at The University of California, San Francisco.
Dr. Faller received a doctorate from Harvard University, a doctorate from Massachusetts Institute of Technology and a graduate degree from The University of California, San Francisco. |
| Roger J. Pomerantz |
Roger J. Pomerantz is a businessperson who has been at the helm of 14 different companies. He occupies the position of Independent Chairman for CollPlant Biotechnologies Ltd., Chairman at Silicon INSITE, Inc., Chairman of Viracta Therapeutics, Inc., Chairman at Viracta Subsidiary, Inc. (a subsidiary of Viracta Therapeutics, Inc.), Chairman of Indaptus Therapeutics, Inc. and President for Pomerantz Life Sciences Consulting Group LLC. He is also on the board of X-Vax Technology, Inc.
Roger J. Pomerantz previously was Chairman, President & Chief Executive Officer of ContraFect Corp., Chairman of Seres Therapeutics, Inc., Senior VP & Head-Licensing & Acquisitions at Merck & Co., Inc., Professor at Molecular Pharmacology (USA) Ltd., Senior Partner at Flagship Pioneering, Chairman at Sunesis Pharmaceuticals, Inc., Chairman of Intec Pharma Ltd., Chief Executive Officer for Tibotec Pharmaceuticals, President of Janssen R&D Ireland Ltd., President at Janssen Therapeutics, Inc., Chief Resident at The General Hospital Corp., Global Head-Infectious Diseases at Johnson & Johnson Pharmaceutical Group, Chairman at Institute of Human Virology, Professor at Thomas Jefferson University and Professor at Sidney Kimmel Medical College.
Roger J. Pomerantz received an undergraduate degree from The Johns Hopkins University and a doctorate from The Johns Hopkins University School of Medicine. |
| Lisa Rojkjaer |
Currently, Lisa Rojkjaer holds the position of Chief Medical Officer for Viracta Therapeutics, Inc. and Chief Medical Officer of Viracta Subsidiary, Inc. (a subsidiary of Viracta Therapeutics, Inc.).
In the past Dr. Rojkjaer occupied the position of Chief Medical Officer of Molecular Partners AG, Chief Medical Officer for Nordic Nanovector ASA, Vice President & Head-Clinical Development at MorphoSys AG, Chief Medical Officer at Sunesis Pharmaceuticals, Inc., Head-AML Global Clinical Program at Novartis Oncology, Inc., Head-Clinical Development & Hematology at Novo Nordisk, Inc. and Head-Global Clinical Program at Novartis Pharma AG.
Lisa Rojkjaer received a doctorate from the University of Toronto. |
| Daniel R. Chevallard |
Daniel R. Chevallard holds the position of Secretary, Chief Operating & Financial Officer at Viracta Therapeutics, Inc. and Chief Financial Officer of Viracta Subsidiary, Inc. (a subsidiary of Viracta Therapeutics, Inc.).
In the past he occupied the position of Chief Financial & Accounting Officer at Regulus Therapeutics, Inc., Chief Financial Officer & Secretary of Sunesis Pharmaceuticals, Inc. and Controller & Senior Director-Finance at Prometheus Laboratories, Inc.
Mr. Chevallard received an undergraduate degree from the University of San Diego. |
| Ivor Royston |
Ivor Royston is an entrepreneur and businessperson who founded Hybritech, Inc., Forward Ventures Services LLC, IDEC Pharmaceuticals Corp. and IDEC Corp. (United States) and who has been at the head of 7 different companies. Presently, Dr. Royston holds the position of President, Chief Executive Officer & Director at Viracta Therapeutics, Inc. and President, Chief Executive Officer & Director at Viracta Subsidiary, Inc. (a subsidiary of Viracta Therapeutics, Inc.). Dr. Royston is also on the board of Viropro, Inc., Biocept, Inc. and CONNECT.
In the past Dr. Royston was Director-Clinical Immunology at San Diego Cancer Center, Managing Member at Forward Ventures Services LLC, Director at Morphotek, Inc., Chairman for TargeGen, Inc., President, Chief Executive Officer & Director at Sunesis Pharmaceuticals, Inc., Director at LigoCyte Pharmaceuticals, Inc., President & Chief Executive Officer at Sidney Kimmel Cancer Center and Member of the University of California San Diego.
Ivor Royston received a doctorate and an undergraduate degree from The Johns Hopkins University. |
| Stephen Rubino |
Stephen Rubino is on the board of Sermonix Pharmaceuticals LLC and Viracta Therapeutics, Inc. and Chief Business Officer for Celyad Oncology SA.
Dr. Rubino previously held the position of Head-Global Solid Tumor at Schering-Plough Europe SA, Global Head-Business Development at Novartis Pharmaceuticals Corp. and Chief Business & Strategy Officer at Omega Therapeutics, Inc.
Dr. Rubino received a doctorate from Weill Cornell Medical College and an MBA from Baruch College. |
| Thomas E. Darcy |
Thomas E. Darcy founded Tocagen, Inc. Mr. Darcy is on the board of Lytx, Inc., YMCA of San Diego County and Viracta Therapeutics, Inc.
Mr. Darcy previously held the position of Executive Vice President-Strategic Projects at Science Applications International Corp., Executive Vice President-Strategic Projects at Leidos Holdings, Inc. and Executive Vice President-Strategic Projects at Leidos, Inc. (a subsidiary of Leidos Holdings, Inc.), Director at Tocagen, Inc. and Audit Partner at PricewaterhouseCoopers LLP.
Mr. Darcy received an undergraduate degree from San Diego State University. |
| Nicole M. Onetto |
Nicole M. Onetto is on the board of Basilea Pharmaceutica AG, Bolt Biotherapeutics, Inc. and Viracta Therapeutics, Inc.
In the past Dr. Onetto was Senior Director-Medical Affairs at Bristol Myers Squibb Co. and Chief Medical Officer & Senior Vice President for ZymoGenetics, Inc. (a subsidiary of Bristol Myers Squibb Co.), Senior Vice President-Medical Affairs at Gilead Sciences, Inc. and Vice President-Medical Affairs of NeXstar Pharmaceuticals, Inc. (a subsidiary of Gilead Sciences, Inc.), Chief Medical Officer & Executive Vice President at OSI Pharmaceuticals, Inc. and Deputy Director & Chief Scientific Officer at Ontario Institute for Cancer Research.
Nicole M. Onetto received a graduate degree from the University of Montréal and a doctorate and an undergraduate degree from Université de Paris 5 René Descartes. |
| Barry J. Simon |
Presently, Barry J. Simon is Chairman, President & Chief Executive Officer for Brink Biologics, Inc. and Director & Chief Corporate Affairs Officer at ImmunityBio, Inc. He is also on the board of Viracta Therapeutics, Inc.
In his past career Dr. Simon held the position of Chairman at Cue Biopharma, Inc., Vice President at Roche Holding AG and Vice President at Roche Diagnostics Corp. (a subsidiary of Roche Holding AG), Vice President of HealthPro BioVentures LLC, Vice President for North Sound Capital LLC, Vice President-Clinical & Regulatory Affairs at iTherX Pharmaceuticals, Inc., President, Director & Chief Administrative Officer at NantKwest, Inc. and Vice President of Immunomedics, Inc.
Dr. Simon received a doctorate from State University of New York at Downstate Medical Center. |
